Olema Pharmaceuticals, Inc.

NasdaqGS:OLMA Stock Report

Market Cap: US$426.7m

Olema Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:OLMA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
13 Dec 24BuyUS$4,730,137Logos Global Management, L.P.Company700,761US$6.75
13 Dec 24SellUS$4,730,137Logos Global Management, L.P.Company700,761US$6.75
11 Dec 24SellUS$986,365Sean BohenIndividual109,502US$9.39
11 Dec 24SellUS$316,703Shane William KovacsIndividual35,159US$9.39
11 Dec 24SellUS$250,456Naseem ZojwallaIndividual27,805US$9.39
11 Dec 24SellUS$147,956Cyrus HarmonIndividual16,393US$9.39
11 Dec 24SellUS$234,916David MylesIndividual26,066US$9.39
01 Aug 24SellUS$35,796,000Paradigm Biocapital Advisors LPCompany2,400,000US$14.92
04 Jun 24SellUS$17,448,750Logos Global Management, L.P.Company1,175,000US$14.85

Insider Trading Volume

Insider Buying: OLMA insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of OLMA?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders3,136,2954.23%
General Public7,954,15610.7%
Hedge Funds11,269,78915.2%
VC/PE Firms11,470,21415.5%
Institutions40,372,73454.4%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 35.8%.

Top Shareholders

Top 25 shareholders own 76.41% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.1%
Bain Capital Life Sciences Investors, LLC
7,470,214US$43.0m0%4.67%
7.77%
BVF Partners L.P.
5,766,189US$33.2m-36.9%1.08%
7.42%
Paradigm Biocapital Advisors LP
5,503,600US$31.6m-30.4%1.21%
5.39%
Deep Track Capital, LP
4,000,000US$23.0m0%0.73%
5.19%
BlackRock, Inc.
3,847,471US$22.1m-3.8%no data
4.97%
Point72 Asset Management, L.P.
3,687,374US$21.2m14.3%0.05%
4.36%
Logos Global Management, L.P.
3,233,875US$18.6m0.78%2.36%
3.61%
BioImpact Capital LLC
2,680,596US$15.4m0.97%2.71%
3.41%
The Vanguard Group, Inc.
2,532,892US$14.6m-7.65%no data
2.65%
State Street Global Advisors, Inc.
1,969,963US$11.3m1.13%no data
2.25%
Pictet Asset Management Limited
1,667,459US$9.6m0%0.01%
2.03%
Candriam, Société En Commandite Par Actions
1,506,764US$8.7m42.3%0.02%
2.03%
Vivo Capital, LLC
1,505,862US$8.7m-19.6%0.74%
1.86%
Dimensional Fund Advisors LP
1,376,924US$7.9m-18.3%no data
1.82%
Woodline Partners LP
1,354,186US$7.8m58.8%0.07%
1.69%
Citadel Advisors LLC
1,252,745US$7.2m847%0.01%
1.35%
Wellington Management Group LLP
1,002,685US$5.8m10.8%no data
1.35%
Great Point Partners, LLC
1,000,000US$5.7m25.5%2.32%
1.26%
Geode Capital Management, LLC
934,929US$5.4m-11.8%no data
1.19%
Cyrus Harmon
886,168US$5.1m1.47%no data
1.15%
Victory Capital Management Inc.
851,512US$4.9m9.9%no data
1.03%
David Myles
766,010US$4.4m3.27%no data
0.96%
Balyasny Asset Management L.P.
709,097US$4.1m0%0.01%
0.88%
Tavistock Life Sciences
650,000US$3.7m0%0.26%
0.73%
Shane William Kovacs
543,549US$3.1m12.1%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 08:55
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Olema Pharmaceuticals, Inc. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Arlinda LeeCanaccord Genuity
Naureen QuibriaCapital One Securities, Inc.
Zegbeh JallahCapital One Securities, Inc.